In this article, we will be taking a look at the Top 10 Hot Stocks with the Highest Upside Potential.

On June 30, Reuters reported that rising stock market valuations, big swings in the value of trillion-dollar companies, and sharp market selloffs have raised concerns that parts of the US stock market may be in a bubble.

Investors have been questioning the strong gains in artificial intelligence and semiconductor stocks, wondering if Wall Street is creating another speculative bubble. Those concerns grew last week after technology stocks declined sharply. The selloff was linked to worries about AI spending being funded by debt and worries over a hawkish Federal Reserve.

While these concerns remain, stocks have stabilized as investors continue to find support in improving market sentiment, broader market participation, and strong corporate earnings.

Oliver Shale, US investment specialist at Britain-based Ruffer, said:

“Looking through the lens of valuations, positioning, and sentiment … all measures of asymmetry and risk are ​flashing amber.”

He noted that some valuation measures are close to record highs, while certain sentiment indicators are flying high. Shale added that “none ​of this is to say that the end is nigh, but that is a fragile setup for any market.”

With this background in mind, let’s take a look at the top 10 hot stocks with the highest upside potential.

Our Methodology

To compile our list of the top 10 hot stocks with the highest upside potential, we looked for stocks that have gained at least 50% in the last 6 months as of June 29, 2026. Next, we focused on the stocks that analysts believe have the most potential for growth. Finally, we ranked the top 10 hot stocks with the highest upside potential based on their average price target upside potential according to analysts as of June 29, 2026. These stocks are also popular among elite hedge funds.

Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

Top 10 Hot Stocks with the Highest Upside Potential

10. Par Pacific Holdings, Inc. (NYSE:PARR)

6-Month Performance: 54.23%

Average Price Target Upside Potential According to Analysts: 40.95%

Par Pacific Holdings, Inc. (NYSE:PARR) ranks among the top 10 hot stocks with the highest upside potential. On May 27, Mizuho upgraded its rating on Par Pacific Holdings, Inc. (NYSE:PARR) from Neutral to Outperform and raised the price target from $58 to $79.

The research firm pointed to the company’s strong Q1 2026 results, a favorable distillate-driven margin backdrop, and “optionality” from small refinery exemption-related benefits.

In Q1 2026, Par Pacific Holdings, Inc. (NYSE:PARR) reported net income attributable to shareholders of $54.5 million, or $1.10 per diluted share. This marked a significant improvement from a net loss of $30.4 million, or $0.57 per diluted share, in the same quarter of 2025. Adjusted EBITDA also increased sharply and reached $91.5 million, compared with $10.1 million in the first quarter of 2025.

The company achieved record refining throughput in Hawaii of 89.8 Mbpd. Par Pacific Holdings, Inc.’s (NYSE:PARR) Hawaii renewable fuels facility also began commercial operations in April. In addition, Par Pacific repurchased $28.0 million worth of its common stock at an average price of $37.96 per share during the quarter.

Par Pacific Holdings, Inc. (NYSE:PARR) is an energy company that provides both conventional and renewable fuels to the western United States.

9. Venture Global, Inc. (NYSE:VG)

6-Month Performance: 55.98%

Average Price Target Upside Potential According to Analysts: 46.12%

Venture Global, Inc. (NYSE:VG) ranks among the top 10 hot stocks with the highest upside potential. On June 17, Venture Global, Inc. (NYSE:VG) announced that it had executed new binding agreements with EnBW for the supply of about 0.82 million tonnes per annum (MTPA) of US liquefied natural gas.

The agreement will run for around five years, starting in 2026. LNG will be supplied from Venture Global, Inc.’s (NYSE:VG) portfolio. These new agreements are in addition to the companies’ existing long-term sales and purchase agreements (SPAs) for 2 MTPA for 20 years.

Earlier, on June 11, Venture Global, Inc. (NYSE:VG) and ATLANTIC – SEE LNG TRADE S.A. also reported an expansion of their existing sales and purchase agreement for US liquefied natural gas.

Under the expanded deal, ATLANTIC – SEE LNG TRADE S.A. is doubling its existing contract with the company from a minimum of 0.5 MTPA to 1.0 MTPA. This 20-year agreement is expected to start in 2030.

Venture Global, Inc. (NYSE:VG) is an American company that produces and exports liquefied natural gas (LNG).

8. Oruka Therapeutics, Inc. (NASDAQ:ORKA)

6-Month Performance: 193.20%

Average Price Target Upside Potential According to Analysts: 46.80%

Oruka Therapeutics, Inc. (NASDAQ:ORKA) ranks among the top 10 hot stocks with the highest upside potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the stock.

This update comes after AbbVie announced that it is acquiring Apogee Therapeutics. AbbVie said that it has entered into a definitive agreement to acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis (AD) and asthma.

Apogee’s pipeline includes zumilokibart (APG777), a lead asset. It is a subcutaneous half-life extended monoclonal antibody that targets IL-13 and is being developed as a treatment for atopic dermatitis. The company is also developing APG273, a combination of zumilokibart and APG333, an anti-TSLP half-life extended monoclonal antibody, for the treatment of asthma.

H.C. Wainwright noted that both Apogee and Oruka Therapeutics, Inc. (NASDAQ:ORKA) were created by privately-held Paragon Therapeutics and share several similarities. The firm said both companies focus on developing treatments for inflammatory and immune-related diseases, with a particular emphasis on inflammatory skin conditions.

Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a biopharmaceutical company focused on developing novel biologics for the treatment of chronic skin diseases.

7. AbCellera Biologics Inc. (NASDAQ:ABCL)

6-Month Performance: 113.29%

Average Price Target Upside Potential According to Analysts: 49.05%

AbCellera Biologics Inc. (NASDAQ:ABCL) ranks among the top 10 hot stocks with the highest upside potential. On June 5, AbCellera Biologics Inc. (NASDAQ:ABCL) reported that it has appointed Dr. Victor Sandor, M.D.C.M, to its Board of Directors as an independent director.

Dr. Sandor is a medical oncologist with extensive experience in developing companies and helping bring new medicines to patients. He previously served as Chief Medical Officer at Array BioPharma, where he played a key role in securing approval for Braftovi (encorafenib) and Mektovi (binimetinib).

Earlier, on May 21, Truist Securities increased its price target on AbCellera Biologics Inc. (NASDAQ:ABCL) from $10 to $12 while keeping its Buy rating on the stock. The firm pointed to positive Phase 1 results for ABCL-635, which showed target engagement and a clean safety profile. This could lead to a better safety profile than competitors.

The research firm said that it is now looking ahead to Phase 2 data expected in the third quarter of 2026. It expects the data to match or exceed the effectiveness seen with Veozah and Lynkuet. Truist believes AbCellera Biologics Inc. (NASDAQ:ABCL) offers an attractive risk-reward opportunity before those results are released.

AbCellera Biologics Inc. (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for endocrinology, women’s health, immunology, and oncology.

6. Alumis Inc. (NASDAQ:ALMS)

6-Month Performance: 152.63%

Average Price Target Upside Potential According to Analysts: 49.62%

Alumis Inc. (NASDAQ:ALMS) ranks among the top 10 hot stocks with the highest upside potential. As of June 29, analysts are bullish on Alumis Inc. (NASDAQ:ALMS), giving the stock a consensus Buy rating. The 12-month median price target of $39.50 set by analysts indicates a potential upside of 49.62% from the current stock price.

On May 15, Stifel reaffirmed its Buy rating on Alumis Inc. (NASDAQ:ALMS) and maintained a $44 price target after the company released its first-quarter 2026 update. The firm highlighted the full Phase 3 data for envudeucitinib, a TYK2 inhibitor, which was presented at the American Academy of Dermatology meeting in March. The data showed that PASI responses continued to deepen through week 24.

Alumis Inc. (NASDAQ:ALMS) expects to submit its New Drug Application in the fourth quarter of 2026, compared with its earlier guidance of the second half of 2026. The company is also expected to report longer-term data during the second half of 2026.

Earlier, on May 14, Guggenheim also increased its price target on Alumis Inc. (NASDAQ:ALMS) from $32 to $34 while keeping its Buy rating. The firm pointed to the company’s first-quarter earnings and clinical trial updates, including detailed data from the Phase III ONWARD1 and ONWARD2 studies of envudeucitinib.

Alumis Inc. (NASDAQ:ALMS) is a late-stage biopharma company focused on leveraging its proprietary data analytics platform and precision approach to develop next-generation targeted therapies for a range of immune-mediated diseases.

Click to continue reading and see the Top 5 Hot Stocks with the Highest Upside Potential.

Disclosure: None. Follow Insider Monkey on Google News.